Applying Current Evidence on Therapeutic Strategies to Improve Outcomes for Patients With MPNs

Join us for this live, interactive, online webinar for an expert discussion of current best practices and emerging strategies in treating patients with myeloproliferative neoplasms (MPNs). Sign up today!


Welcome and introduction
Overview of current diagnostic criteria and risk stratification for MPNs
Case studies: myelofibrosis

  • Managing patients with no prior treatment or ruxolitinib failure, including those with anemia
  • Emerging investigational agents and combinations

Case studies: polycythemia vera

  • Managing patients with no prior treatment or HU failure
  • Emerging investigational agents and combinations

Case studies: essential thrombocythemia

  • Managing patients with no prior treatment
  • Emerging investigational agents and combinations

Audience question and answer section


Date / Time
Event Details


Prithviraj Bose, MD

Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Stephen Oh, MD, PhD

Assistant Professor
Division of Hematology
Department of Medicine
Washington University School of Medicine
St Louis, MO

Brady L. Stein, MD, MHS

Associate Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Goal Statement

The goal of this activity is to improve the knowledge and competence of learners in treating patients with myeloproliferative neoplasms.

Target Audience

This program is intended for physicians and other HCPs who care for patients with MPNs, including ET, PV, and MF.

Learning Objectives

  • Navigate safety and efficacy data for emerging treatment options and novel formulations used in the management of MPNs
  • Develop individualized treatment plans for patients with MPNs based on risk stratification and symptom burden
  • Plan management strategies for patients with MF with anemia and/or thrombocytopenia
  • Discuss the most recent scientific findings and how this novel information will continue to shape the clinical landscape in the future


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.